"...few treatment emergent adverse events..." is very vague and doesn't say how severe those events may have been and if they caused the person to no longer be able to tolerate leronlimab. It would be nice to know both.

Also, 28 patients is not as big a number as I would like to see. I wonder how potential partners and the FDA will feel.